SuperworthAtrium Therapeutics revenue RNA
Sales by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- $3M
- −22% on a year earlier
Atrium Therapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was $3M, down 22% on the same quarter a year before.
Revenue over time
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier |
|---|---|---|---|
| Q2 FY26 | $3M | −22% | |
| Q1 FY26 | $19.6M | +1148% | |
| Q2 FY25 | $3.8M | n/a | |
| Q1 FY25 | $1.6M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Atrium Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| RNAAtrium Therapeutics | n/m | |
| NATRNatures Sunshine Products | $492M | +7% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| ARVNArvinas | $316.7M | −15% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| Peer median | $316.7M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Atrium Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.